AB Science : Positive Phase 2 Clinical Study Data of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science : Positive Phase 2 Clinical Study Data of Masitinib in Triple Negative Breast Cancer

AB Science Reports Positive Phase 2 Clinical Study Data of Masitinib in Triple Negative Breast Cancer

Data submitted for publication to the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting

Paris, France, March 12, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced positive efficacy and safety results from a phase 2 study with masitinib in patients with triple negative breast cancer (TNBC).

This was a prospective, multicenter, open-label, randomized, uncontrolled, phase 1b/2 study to evaluate efficacy and safety of masitinib in association with chemotherapy for the treatment of TNBC. Patients received masitinib in combination with carboplatin and/or gemcitabine.

In the cohort receiving masitinib in combination with carboplatin and gemcitabine, 37% of patients enrolled were in first-line of treatment, 16% were in second-line of treatment and 47% were in third-line of treatment or beyond. For the overall cohort, median overall survival was 10.2 months and median progression-free survival was 4.7 months. Objective response rate was 43%.

The efficacy of masitinib in combination with carboplatin and gemcitabine compares favorably to median OS of 7.7 months and response rate of 32% published for carboplatin plus gemcitabine in the treatment of TNBC 1 .

A statistical test was pre-defined in this phase 2 study in order to detect a superiority trend on the overall survival between the median value of the study and historical median value. The result of this test enables to determine whether or not a confirmatory phase III could be initiated. This statistical test is based on the upper bound for the confidence interval of Hazard Ratio lower than 1, estimated from the median Overall Survival (OS) observed in this phase 2 study and the historical benchmark. In the masitinib + gemcitabine + carboplatin group, upper bound of the confidence interval for OS hazard ratio is estimated to 0.70, permitting to justify the launch of a larger study. AB Science is currently discussing with the experts of the disease the next steps of clinical development.

Full safety and efficacy data has been submitted for publication to the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.

"The phase 2 efficacy results of masitinib in combination with carboplatin and gemcitabine for the treatment of advanced triple negative breast cancer are quite encouraging," said Professor Mario Campone of the Institut de Cancérologie de l'Ouest, Nantes, France, and the principal investigator of this study. "A significant unmet medical need still exists for treatment of advanced triple negative breast cancer, and the development of targeted agents such as masitinib in combination with cytotoxic drugs has potential to improve patient survival in this disease."

TNBC is more aggressive than other forms of breast cancer, with fewer treatment options and no drug registered in this specific indication. The benchmark for median overall survival in metastatic breast cancer is estimated at 18 months 2 in second-line of treatment, TNBC not included, whereas it is less than 7.7 months in second-line treatment of TNBC. Hence, there is still a high unmet medical need in this disease.

Breast cancer remains the second most common cancer in the world, and kills more women than any other cancer type. The incidence of breast cancer is reported as approximately 600,000 patients in the USA and Europe, and the mortality rate was of 130,000 patients 3 . It is estimated that 15% of patients have TNBC.

It is also estimated that up to 40% of those diagnosed with breast cancer will develop advanced disease within 10 years.

With these hypotheses, the number of eligible patients for treatment of advanced triple negative breast cancer is estimated to be 36,000 per annum in Europe and USA.

1 Shaughnessy. N Engl J Med 2011;364:205-14. / Note :The referenced study enrolled 60% of patients in first-line, and 40% in second-line or beyond.

2 References from meta-analysis
[1] Kaufmann M et al, Eur J Cancer, 2010 Dec; 46(18):3184-91
[2] Barrios CH et al, Breast Cancer Res Treat. 2010 May;121(1):121-31
[3] Sparano J et al, J Clin Oncol. 2010 Jul 10;28(20):3256-63
[4]Stockler M et al, J Clin Oncol. 2011 Dec 1;29(34):4498-504
[5]Robert NJ et al, C Clin Oncol. 2011 Apr 1;29(10)
[6]Baselga J et al, J Clin Oncol. 2012 May 1;30(13)
[7]Blum LJ et al, Breast Cancer Res Treat. 2012 Dec;136(3):777-88
[8]Park Y et al, Journal of tumor, 2014 April 18 2(4):113-121

3 http://eco.iarc.fr/eucan/ ; http://seer.cancer.gov/statfacts/html/breast.html

Status of masitinib clinical development in human medicine
Masitinib is currently developed in 13 phase III indications; 7 in oncology, 3 in inflammatory diseases, and 3 in neurodegenerative diseases. Additionally, a large phase II clinical program is ongoing, mainly in oncology. In case of positive results, phase III studies will be initiated following these phase II studies. Overall, clinical development has been initiated in more than 30 countries, without any licensing agreement. Therefore, AB Science has retained full ownership of masitinib.

About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.
AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

*   *   *

AB Science - Financial Communication & Media Relations

investors@ab-science.com

AB Science Eng http://hugin.info/155655/R/1903026/676772.pdf

HUG#1903026

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Arcline Investment Management Sells Resolution Medical to Resonetics

Updated Category News Views 213

Arcline Investment Management Sells Resolution Medical Arcline Investment Management, a dynamic private equity firm, has made a notable move in the medical technology landscape. The firm is set to sell its portfolio company, Resolution Medical, to Resonetics. This strategic decision highlights Arcline's ongoing commitment to advancing innovative solutions within the...

Continue Reading
Cheetah Mobile Surges with Impressive Q2 Financial Results

Updated Category News Views 223

Cheetah Mobile Reports Strong Growth in Q2 2025 Cheetah Mobile Inc. (NYSE: CMCM), a prominent IT company, has recently reported its financial results for the second quarter of 2025. The results indicate a remarkable increase in total revenue and profitability, showcasing the company’s ongoing strategic transformation. Management Insights on Performance Mr. Sheng Fu,...

Continue Reading
OwlTing Group Launches OwlPay Harbor for Enhanced Payment Solutions

Updated Category News Views 287

OwlTing Group Transforms Payments with AI-Powered OwlPay Harbor OwlTing Group, a pioneering blockchain fintech firm, has announced a significant evolution of its payment platform, OwlPay Harbor. This innovative service integrates artificial intelligence to enhance the experience for developers and users alike, making financial transactions faster and more secure than ever...

Continue Reading
Colt DCS Taps Nguyen for CEO Amid Growth Surge

Updated Category News Views 24

Nguyen Takes Helm at Colt DCS Well, here's a move that'll definitely shake the data center landscape a bit: Quy Nguyen's stepping up as the Chief Executive Officer at Colt Data Centre Services. From temporary to permanent, that decision speaks volumes about the trust in his leadership acumen during these transformative times. Colt's apparently betting the farm on Nguyen...

Continue Reading
NWR Storage Containers Expands with New Facility Opening

Updated Category News Views 143

NWR Storage Containers Expands with New Facility Opening NWR Storage Containers, a prominent provider of storage container rentals, is excited to announce its relocation to a larger facility. This event marks a significant step forward in their journey of growth and commitment to serving customers effectively. Relocation to a New Facility The newly established operations...

Continue Reading